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Abstract
Only a few cases of extranodal Epstein-Barr virus (EBV)-associated B-cell lymphomas arising from patients with
angioimmunoblastic T-cell lymphoma (AITL) have been described. We report a case of AITL of which secondary
cutaneous EBV-associated diffuse large B-cell lymphoma (DLBCL) developed after the initial diagnosis of AITL. A 65-
year-old Chinese male patient was diagnosed as AITL based on typical histological and immunohistochemical
characteristics in biopsy of the enlarged right inguinal lymph nodes. The patient initially received 6 cycles of
chemotherapy with CHOP regimen (cyclophosphamide, vincristine, adriamycin, prednisone), but his symptoms did
not disappear. Nineteen months after initial diagnosis of AITL, the patient was hospitalized again because of
multiple plaques and nodules on the skin. The skin biopsy was performed, but this time the tumor was composed
of large, polymorphous population of lymphocytes with CD20 and CD79a positive on immunohistochemical
staining. The tumor cells were strong positive for EBER by in situ hybridization. The findings of skin biopsy were
compatible with EBV-associated DLBCL. CHOP-R chemotherapy (cyclophosphamide, doxorubicin, vincristine,
prednisone and rituximab) was then administered, resulting in partial response of the disease with pancytopenia
and suppression of cellular immunity. To our knowledge, this is the first case of cutaneous EBV-associated DLBCL
originated from AITL in Chinese pepole. We suggest the patients with AITL should perform lymph node and skin
biopsies regularly in the course of the disease to detect the progression of secondary lymphomas.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/1197421158639299
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Background
Angioimmunoblastic T-cell lymphoma (AITL) is one of
the most common subtypes of peripheral T-cell lympho-
mas, accounting for approximately 15-20% of all cases, or
1-2% of all non-Hodgkin lymphomas [1]. AITL is fre-
quently accompanied by a polymorphic nature including
fever, skin eruptions, polyclonal hypergammaglobulinemia,
generalized lymphadenopathy and hepatosplenomegaly
[2]. Histopathologically, the primary site of AITL is lymph
node characterized by the effacement of the lymph node
architecture, the increase of arborizing high endothelial
venules and the infiltration of clear small- to medium-
sized lymphocytes, along with the increase of B-immuno-
blasts that usually contain Epstein-Barr virus (EBV). AITL
patients exhibit immunodeficiency secondary to the neo-
plastic process. Expansion of EBV-positive B cell is
thought to be a consequence of underlying immune dys-
function [3]. In rare condition, secondary EBV-associated
B cell lymphoma may occur together with AITL. However,
to our knowledge, so far only 22 cases of AITL developed
EBV-associated secondary B cell lymphomas have been
described in English literature [4-14]. Herein, we report a
case of secondary EBV-associated diffuse large B cell
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node AITL.
Case presentation
A 65-year-old Chinese male patient presented with a 6-
month history of enlarged right inguinal lymph nodes
without pain and fever and initially sought examination
and treatment at our hospital in September, 2009. Physi-
cal examination revealed multiple enlarged lymph nodes
easily identified in the right inguinal region, and the
spleen was palpable 2 cm below the left costal margin
without discrete masses or tenderness. Maculopapular
eruptions could be found in the trunk. There was no
remarkable edema and masses observed in the skin. The
laboratory results including blood count, differential,
liver and renal function were within the normal range.
Eosinophilia and hypergammaglobulinemia were not
observed. Computed tomography (CT) scan disclosed
the enlargement of right inguinal and visceral lymph
nodes, as well as hepatosplenomegaly. Test for EBV
exhibited both viral capsid antigen (VCA) and EBV-
associated antigen positive.
The patient then underwent biopsy of right inguinal
lymph node, but the biopsy of skin lesion was not per-
formed at that time. The biopsy tissue was routinely
processed and stained by hematoxylin and eosin (H&E).
Under the microscopy, the normal architecture of
lymph node was destroyed by polymorphic cellular infil-
tration composed of diffused small to medium-sized
lymphoid cells along with plasma cells and eosinophils.
The infiltrated lymphocytes had clear cytoplasm with
mildly irregular nuclei. Some of large immunoblast-like
lymphoid cells with large distinct nuclei and clear cyto-
plasm were observed to intermingle with those infil-
trated lymphocytes. Numerous arborizing high-
endothelial venules were prominent in the background
of lymph node. In addition, scattered Reed-Sternberg
(RS)-like cells with irregular multilobated nuclei and
large eosinophilic nucleoli were also present in the node
(Figure 1A-B). Immunohistochemically, the infiltrated
small to medium-sized lymphoid cells were strongly
positive for CD3, CD45RO, CD10 and CD4, but nega-
tive for CD20, CD79a, PAX-5, CD56, MUM-1 and
CD30. The large immunoblast-like cells and scattered
RS-like cells showed immunoreactive for CD20, CD79a
and CD30. The proliferation of follicular dendritic cells
highlighted by CD21 and CD23 was prominent through-
out node, and entrapped the high-endothelial venules.
By in situ hybridization assay, EBER-positive signal was
observed in either scattered large B immunoblasts or
RS-like cells (Figure 1C-F). Based on clinical presenta-
tion and histological findings, a histological diagnosis of
angioimmunoblastic T-cell lymphoma (AITL) was made
according to the criteria of WHO classification [3].
After the diagnosis of AITL, the patient received 6
cycles of chemotherapy with CHOP regimen (cyclopho-
sphamide, vincristine, adriamycin, and prednisone), but
his symptoms did not disappear. The patient was fol-
lowed up without any treatment for nearly one year
after completing the whole chemotherapy courses.
There was no further complaint from the patient during
the follow-up period. In April, 2011, nineteen months
after initial diagnosis the patient was readmitted to our
hospital due to presentation of multiple plaques and
nodules on the skin. Skin examination showed irregular
plaques and nodules ranging from 0.5 to 2.5 cm in dia-
meters in the trunk and extremities. CT scan revealed
multiple enlargements of right inguinal and visceral
lymph nodes as well as hepatosplenomegaly. Bone mar-
row aspiration was normal. The skin biopsies were per-
formed in the skin lesion located at the left upper arm.
Microscopically, dermal and subcutaneous tissue was
infiltrated by sheets of a monotonous population of
medium- to large-sized atypical lymphoid cells without
epidermotropism. Cellular atypia exhibited irregular
nuclei, large nucleoli and vesicular chromatin with a
brisk mitotic rate, atypical mitotic figures (Figure 2A-B).
Immunohistochemically, the atypical cells were strongly
positive for CD20, CD79a and Bcl-6, but negative for
CD3, CD5, and CD45RO. EBV detection by in situ
hybridization for EBERs showed diffuse positive reaction
(Figure 2C-F). These findings were compatible with dif-
fuse large B cell lymphoma (DLBCL). Sections of the
lymph node biopsy performed one year earlier were
reviewed. The structure and cytologic features of skin
lesion were distinct from those of the lymph node.
There was a diffuse infiltrate of predominantly small to
medium-sized lymphocytes with unambiguous T cell
markers by immunohistochemical analysis in lymph
node. These tumor cells were negative reaction to EBER
assay. However, the infiltrated large sized neoplastic
cells in the skin lesion were identified as B lymphocytes
and positive to EBER assay. Based on these findings, a
histological diagnosis of AITL-developed secondary
EBV-associated DLBCL of skin was made.
After diagnosis, the patient received a cycle of R-
CHOP regimen (rituximab, cyclophosphamide, doxoru-
bicin, vincristine, and prednisone) and achieved a partial
response. However, pancytopenia and suppression of
cellular immunity were observed. The patient refused
further treatment of R-hyperCVAD regimen (rituximab,
cyclophosphamide, vincristine, doxorubicin, and dexa-
methasone) and was discharged from hospital. The
further following up was not performed due to contact
loss of the patient.
Angioimmunoblastic T-cell lymphoma (AITL) was pre-
viously regarded to be an atypical reactive process. In 1974,
Frizzera et al. firstly termed it as “angioimmunoblastic
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Page 2 of 8Figure 1 Histopathological findings of lymph node at the initial presentation. (A) The architecture of lymph node was effaced by a diffuse
polymorphic infiltration composed of small- to medium-sized lymphoid cells, immunoblastic cells and scattered eosinophils around high-
endothelial venules. (B) Multinucleated cells with eosinophilic nucleoli resembling Reed-Stemberg (RS) cells could be observed in the lymph
node. (C) Immunohistochemical examination revealed that infiltrated small to medium-sized lymphoid cells were diffusely positive for CD3, but
large immunoblast-like cells and RS-like cells were positive for CD20 (D) and CD30 (E).These larger cells were also positive for EBER by in situ
hybridization (F).(A, H&E staining, with original magnification ×400; B, H&E staining, with original magnification ×600; C-E, immunohistochemical
staining, with original magnification ×400; F, EBER-in situ hybridization, with original magnification ×400).
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Page 3 of 8Figure 2 Histological findings of skin lesion. (A) Low power view of skin lesion showed diffuse infiltration of lymphoid cells in dermal and
subcutaneous tissue without epidermotropism. (B) Large atypical lymphoid cells with prominent nucleoli were observed in the skin lesion.
Atypical large lymphoid cells were stained positively with CD20 (C) and CD79a (D). However, CD3 positive cells in skin lesion were small
lymphocytes with scattered distribution (E). (F) Most of atypical large cells were positive for EBER by in situ hybridization. (A, H&E staining, with
original magnification ×40; B, H&E staining, with original magnification ×400; C-E, immunohistochemical staining, with original magnification
×400; F, EBER-in situ hybridization, with original magnification ×400).
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Page 4 of 8lymphadenopathy with dysproteinemia (AILD)” [15], of
which AILD was described as a reactive lymphoprolifera-
tive disorder of T lymphocytes [16]. AITL was considered
as a malignant transformation of AILD, but the histological
distinguishing AITL from AILD was quite difficult. In the
past, the presence of clusters of cells with abundant clear
cytoplasm was regarded as one of the most important mor-
phological criteria and used to distinguish AITL from
AILD. However, subsequent molecular and cytogenetic
studies revealed that clonal TCR gene rearrangement and
chromosomal abnormalities were identified in the majority
of AILD [17,18], which indicated most cases previously
diagnosed as AILD actually represented AITL. In 2001,
WHO classification of tumor of hematopoietic and lym-
phoid tissue suggested AITL was most likely to arise as a
peripheral T-cell lymphoma. As both terms of AITL and
AILD were in common use, they could be used inter-
changeably in clinics. However, some researchers argued
that a few cases of AILD with atypical or oligoclonal prolif-
eration might precede the development of AITL, and
should be classified as a distinct entity of preneoplastic pro-
cess [19,20]. Although debate remained, we considered
AILD might represent the existence of stages in the devel-
opment of AITL rather than independent disease entities.
Although the pathogenesis of AITL remains unclear, it
is currently thought to most likely derived from germ-
inal-center T-helper cells (TFH) [21]. The primary site of
AITL is lymph node and virtually all patients present
with generalized lymphadenopathy. Histological exami-
nation of the lymph nodes exhibits nearly complete effa-
cement of the follicular architecture, a mixed lymphoid
infiltrate, and numerous high endothelial venules in an
expanded T-cell zone. In some cases, the lymph nodes
show diffuse obliteration of their architecture by lym-
phoid infiltration consisting of lymphocytes, immuno-
blasts, plasma cells, and histiocytes, together with
numerous high endothelial venules surrounded by an
expanded network of follicular dendritic cells. Immuno-
histochemically, the neoplastic cells express most pan
T-cell antigens such as CD2, CD3 and CD5. The major-
ity of the proliferating cells are CD4 positive or, less
often, CD8 positive [3]. Attygalle et al.d e m o n s t r a t e d
that CD10 was a phenotypic marker, which specifically
identified the tumor cells of 90% of AITL [22]. Dorfman
et al. reported that programmed death-1 (PD-1), a
member of the CD28 costimulatory receptor family, is
expressed by germinal center-associated T cells in AITL
[23]. De Leval et al. indicated tumor cells in AITL could
overexpress CXCL13, which is the characteristic of nor-
mal TFH cells [21]. These researchers suggest those
immunophenotypes are helpful to distinguish AITL
from atypical paracortical hyperplasia and other periph-
eral T-cell lymphomas as well as diagnosing extranodal
dissemination. In our case, not only histological
examination of lymph node demonstrated a morphologi-
cal characteristic of AITL, but also the presence of T-
cell linage with aberrant CD4 and CD10 expression
identified in neoplastic cells by immunohistochemical
staining which also strongly supported a diagnosis of
AITL at initial lymph node biopsy.
It is well known that most cases of AITL are fre-
quently complicated with EBV infection, but the neo-
plastic T cells are EBV negative. Almost all cells
infected by EBV are B-cells showing normal histological
findings [3,24]. However, in rare condition, the compli-
cation of EBV-associated B cell lymphoma in AITL has
been reported. The immune dysregulation present in
AITL may have permitted EBV infection or reactivation,
which could play a role in the proliferation of B-cell
immunoblasts and clonal expansion of an immortalized
EBV-infected B-cell clone. Therefore, the development
of B-cell lymphoma can be a consequence of the disease
progression of AITL [3,6]. To the best of our knowl-
edge, so far only 22 cases of AITL-developed secondary
EBV-associated B cell lymphoma have been described in
the literature (Table 1) [4-14]. Similar to our case, most
of previously reported cases showed only AITL on initial
biopsy, and showed B-cell lymphoma (with or without
coexistent AITL) on follow-up biopsy. The time interval
between two tumors ranged from 5 to 96 months. AITL
with simultaneous B-cell lymphoma or primary B-cell
lymphoma in the background of AITL could be found
in 6 cases. “Composite AITL and B-cell lymphoma” was
suggested by Xu et al. when the simultaneous appear-
ance of these two distinct lymphomas developed in the
same anatomic site [6]. It was commonly considered
that secondary EBV-associated B-cell lymphomas in
AITL raised from EBV-infected B cells in lymph node,
and we found indeed that EBV could be detected in
initial AITL in most of previous cases. However, EBV-
infected B-cell was not detected in the 6 cases before
the development of secondary B-cell lymphoma by
EBER-in situ hybridization method. Whether or not spe-
cific mechanism involved in the sequential development
of EBV-associated B-cell lymphoma in AITL derived
from non-EBV-infected cells should be investigated
further. Seven cases have been reported that the second-
ary B-cell lymphoma develop in extranodal organs,
including skin, bone marrow, duodenal bulbous, lung,
ileum and soft tissue [4,7-12], and only two cases as
well as ours presented skin involvement by secondary B-
cell lymphoma [4,8]. The present case is the first report
on cutaneous sequential development of EBV-associated
DLBCL from AITL in Chinese patients. Although the
prognosis of AITL once complicated by EBV-associated
DLBCL is not well known, extranodal involvement of
lymphomas is a poorer sign. We found in previous
AITL cases, the patients with extranodal involvement by
Yang et al. Diagnostic Pathology 2012, 7:7
http://www.diagnosticpathology.org/content/7/1/7
Page 5 of 8Table 1 Clinicopathological features of patients with AITL-developed secondary EBV-associated B cell lymphoma described in present and previous reports
caseNo. Authors (yr.) Age/
sex
Tumor site Interval
(mo)
Histotype of BCL* Treatment Clinical Outcome
AITL BCL AITL BCL
1 Abruzzo LV (1993) [4] 46/M LN SK 26 Large-cell immunoblastic
type
Cyclophosphamide N/D Died of multiorgan failure
2 Park S (2002) [5] 55/F LN LN 48 BCL CHOP CHOP-R CR and alive 12 mo later
3 Xu Y (2002) [6] 48/F LN LN 0 DLBCL CHOP and ESHAP CR and relapsed a few months later
4 Zettl A (2002) [7] 68/M LN ST 34 DLBCL Observation Glucocorticoids Died 4 mo later of tuberculosis
5 47/M LN LN 29 DLBCL CC; BMT CC; involved field radiation Died 3 mo later of Aspergillus
pneumonia
6 61/M LN LN 96 Plasmacytoma N/Av N/Av Alive with disease 24 mo later
7 Hawley RC (2006) [8] 69/F LN SK 56 DLBCL CHOP R-hyperCVAD Died 54 mo later
8 Attygalle AD (2007)
[9]
28/M LN BM 24 DLBCL CHOP Gemcitabine No response and died 3 mo later
9 60/F LN LN 8 DLBCL CHOP CHOP-Et No response and died 3 mo later
10 59/M LN LN 8 DLBCL N/Av CC PR and alive with disease 68 mo
later
11 72/M LN LN 84 DLBCL N/Av N/Av N/A
12 78/F LN LN 0 DLBCL Thalidomide PR
13 Willenbrock K (2007)
[10]
76/F LN LN 8 DLBCL N/Av N/Av N/Av
14 46/F LN BM 5 DLBCL N/Av N/Av N/Av
15 84/M LN LN 0 DLBCL N/Av N/Av N/Av
16 72/M LN LN 0 DLBCL N/Av N/Av N/Av
17 65/M LN LN 0 CD30-positive BCL N/Av N/Av N/Av
18 60/F LN LN 0 DLBCL N/Av N/Av N/Av
19 Weisel KC (2008) [11] 59/M LN DB and
lung
11 DLBCL Fudarabine+
CHOP
N/D Died 2 weeks later
20 Takahashi T (2010)
[12]
66/F LN Ileum 24 DLBCL THPCOP
CHASE
N/D Died 1 mo later of respiratory failure
21 Skugor ND (2010)
[13]
36/F LN LN 11 DLBCL FED CHOP-R and stem cell
transplantation
CR
22 Huang J (2011) [14] 64/M LN LN 47 DLBCL IHOP CHOP-R Alive with disease 13 mo later
23 Present case 65/M LN SK 19 DLBCL CHOP CHOP-R PR
*, all B-cell lymphoma with EBV positive; AITL, angioimmunoblastic T-cell lymphoma; BCL, B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; LN, lymph node; SK, skin; ST, soft tissue; BM, bone marrow; DB,
Duodenal bulbus; Interval 0, AITL with simultaneous B-cell lymphoma or primary B-cell lymphoma in the background of AITL; BMT, bone marrow transplantation; N/Av, not available; N/D, not done; PR, partial
response; CR, complete remission; CHOP, cyclophosphamide, vincristine, adriamycin, and prednisone; ESHAP, etoposide, methyl prednisolone, cytarabine (ara-C) and cisplatin; hyperCVAD, cyclophosphamide,
vincristine, doxorubicin, and dexamethasone; IHOP, ifosfamide, doxorubicin, vincristine, and prednisone; THPCOP, cyclophosphamide, pirarubicin, vincristine, prednisolone; CHASE, cyclophosphamide, cytarabine,
etoposide, dexamethasone; FED, fludarabine, cyclophosphamide, dexamethasone; Et, etoposide; R, rituximab; CC, combination chemotherapy, details not available;
Y
a
n
g
e
t
a
l
.
D
i
a
g
n
o
s
t
i
c
P
a
t
h
o
l
o
g
y
2
0
1
2
,
7
:
7
h
t
t
p
:
/
/
w
w
w
.
d
i
a
g
n
o
s
t
i
c
p
a
t
h
o
l
o
g
y
.
o
r
g
/
c
o
n
t
e
n
t
/
7
/
1
/
7
P
a
g
e
6
o
f
8B-cell lymphoma presented shorter survival time than
those with secondary B-cell lymphoma in lymph nodes.
Based on these data, it is thought the present case
might have an aggressive biological behavior and a less
favorable prognosis.
The presence of large immunoblast cells and scattered
RS-like cells in AITL might create diagnostic confusion
with other neoplastic condition of lymphoid tissue. The
main differential diagnoses include classical Hodgkin
lymphoma (cHL) and T cell/histiocyte-rich large B-cell
lymphoma (THRLBCL). THRLBCL is characterized by a
limited number of scattered, large, atypical B cells
embedded in a background of abundant T cells and fre-
quently histiocytes. Immunohistochemically, large atypi-
cal cells express pan B-cell markers and no expression
of CD30, and are lack of EBV infection. The background
of THRLBCL is composed of variable number of CD68-
positive histiocytes and CD3-, CD5-positive small T
cells rather than CD4-, CD10- and CXCL13-positive
small to medium-sized TFH cells. Numerous high
endothelial venules surrounded by an expanded network
of follicular dendritic cells highlighted by CD21 and
CD23 will be useful to distinguish AITL form
THRLBCL. In this present case, an interesting finding
was the presence of occasional CD30 and EBV-positive
RS-like cells within inflammatory background of lymph
node. This histological finding was similar to the mor-
phological feature of cHL. However, recognition of cyto-
logic atypia or immunophenotypic aberrancy in the
background T cells is critical for making the differential
diagnosis between AITL and cHL.
In conclusion, secondary B-cell lymphoma in AITL is
rare. Herein we report the first case of cutaneous EBV-
associated DLBCL sequential to AITL in Chinese
patients. Extranodal involvement by secondary lym-
phoma in the patients with AITL might imply a poor
prognosis. Therefore, clinicians should keep in mind that
there is a possibility of sequential development of B-cell
lymphoma after AITL. It is necessary to perform lymph
node and skin biopsies regularly to detect the progression
to secondary lymphomas for patients with AITL.
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